Last reviewed · How we verify
Efficacy of Calcium Dobesilate As an Alternative Method for Treatment of Menorrhagia, Comparison to Tranexamic Acid
The goal of this clinical trial is to determine if calcium dobesilate is an effective alternative to tranexamic acid for treating menorrhagia in women aged 18 to 39 years. The main questions it aims to answer are: Does calcium dobesilate reduce menstrual blood loss and improve hemoglobin levels as effectively as tranexamic acid? What side effects and acceptability differences exist between calcium dobesilate and tranexamic acid? Researchers will compare calcium dobesilate to tranexamic acid to see if calcium dobesilate is as effective in reducing heavy menstrual bleeding and improving patient outcomes. Participants will: Take calcium dobesilate or tranexamic acid during their menstrual cycle for three consecutive cycles. Record menstrual blood loss using the Pictorial Blood Loss Assessment Chart (PBAC). Attend follow-up visits after each menstrual cycle to monitor hemoglobin levels, menstrual symptoms, and any side effects.
Details
| Lead sponsor | University of Health Sciences Lahore |
|---|---|
| Phase | NA |
| Status | NOT_YET_RECRUITING |
| Enrolment | 100 |
| Start date | 2025-01-05 |
| Completion | 2025-12 |
Conditions
- Menorrhagia
- Abnormal Uterine Bleeding
Interventions
- Calcium dobesilate (Doxium)
- Tranexamic Acid
Primary outcomes
- Reduction in Menstrual Blood Loss — At the end of the third treatment cycle (each cycle is 28 days).
Menstrual blood loss will be measured using the Pictorial Blood Loss Assessment Chart (PBAC). Participants will record the number and type of sanitary products used (e.g., pads or tampons) and the degree of saturation, along with any clots passed. PBAC scores above 100 are indicative of heavy menstrual bleeding. A reduction in PBAC scores after the third treatment cycle (each cycle lasting 28 days) will be used to determine the effectiveness of the intervention.